Final-Program-ATS-2023-AP.vp

TUESDAY • MAY 23

287

2:54 Importance of Metabolomic Changes in IPF Pathogenesis F. Romero, PhD, Philadelphia, PA 3:06 How Pharmacogenomics and Drug Discovery can Provide New Insights into ILD Pathogenesis L. Hecker, PhD, Atlanta, GA 3:19 Understanding the Systemic Microbiome in IPF D.N. O’Dwyer, BM BCH, BMedSci, PhD, Ann Arbor, MI 3:32 The Multi-Omic Universe: How Do We Integrate These Datasets to Better Understand and Eventually Cure IPF N. Kaminski, MD, ATSF, New Haven, CT This session and the International Conference are supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests). C87 A MEASURED RESPONSE: ASSESSING TREATMENT OUTCOMES IN PULMONARY HYPERTENSION Assemblies on Pulmonary Circulation; Behavioral Science and Health Services Research; Clinical Problems 2:15 PM - 3:45 PM Marriott Marquis Washington Marquis Ballroom Salon 6 (Level M2) Target Audience Providers of patients with pulmonary hypertension, researchers in pulmonary hypertension, clinicians and researchers needing instruction in the evaluation and management of pulmonary hypertension Objectives At the conclusion of this session, the participant will be able to: • describe the strengths and weaknesses of currently employed outcome measures in pulmonary hypertension clinical trials • describe novel outcome measures that focus on “feels, functions, and survives” and how these may be applied in PH clinical trials • more appropriately interpret and integrate results from clinical trials into clinical practice Multiple outcome measures are currently employed in the evaluation and management of patients with pulmonary hypertension (PH), creating confusion about which measure is most appropriate. In this session, we will discuss the state of the art approach to outcomes assessment in PH through in-depth analyses of the current and future measures of therapeutic response. BEHAVIORAL • CLINICAL SCIENTIFIC SYMPOSIUM CME Credits Available: 1.5

BASIC • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 1.5

C86 BEYOND THE TRANSCRIPTOME: HOW THE MULTI-“OMIC” UNIVERSE PROVIDES NOVEL INSIGHTS INTO IPF/ILD PATHOGENESIS Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Clinical Problems 2:15 PM - 3:45 PM Walter E. Washington Convention Center Room 207 A-B (Level 2) Target Audience Basic scientists, clinicians, translational researchers in pulmonary fibrosis Objectives At the conclusion of this session, the participant will be able to: • to understand and recognize how different biologic processes, including genomic, epigenomic, metabolomic, and microbiome changes contribute to the development and pathogenesis of IPF/ILD • to learn how some of these diverse layers of biologic data can be integrated to derive new insights into IPF pathogenesis • To identify challenges to integrating -omics data and identify areas for future research need in IPF/ILD Studies utilizing RNA sequencing and single-cell approaches have identified new cell types, genes, and pathways that contribute to the pathogenesis of lung fibrosis. However, layers of biologic data beyond the transcriptome, including genomic, epigenomic, proteomic, and metabolomic studies have also enhanced our understanding of fibrotic mechanisms. Understanding these multi-omic “universes” and how they interact with the environment and microbiome can help address fundamental questions regarding etiology, prognosis, and strategies for personalized treatment. This session will highlight the current state of knowledge in these other areas and attempt to integrate these data into M.N. Ballinger, PhD, ATSF, Columbus, OH J. Kropski, MD, Nashville, TN 2:15 Into the Genomics and Epigenomics Universe of IPF I.V. Yang, BS, PhD, Aurora, CO 2:28 “ATAC”-ing IPF: how Understanding Chromatin Biology Sheds Light on Fibrosis G. Ligresti, PhD, Boston, MA 2:41 The Next Frontier: Proteomics of Post-translational Modifications in IPF O. Eickelberg, MD, ATSF, Pittsburgh, PA a cohesive understanding of IPF pathogenesis. Chairing: S.K. Huang, MD, Ann Arbor, MI

ATS 2023 • Washington, DC